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Abstract
Background: Heat shock proteins (HSPs) are ubiquitous, highly conserved proteins across all the
species and play essential roles in maintaining protein stability within the cells under normal
conditions, while preventing stress-induced cellular damage. HSPs were also overexpressed in
various types of cancer, being associated with tumor cell proliferation, differentiation and
apoptosis. The aim of the present study was to evaluate the clinical significance of HSP -27, -60, and
-90 expression in gastric carcinoma.
Methods: HSP -27, -60, and -90 proteins expression was assessed immunohistochemically in
tumoral samples of 66 gastric adenocarcinoma patients and was statistically analyzed in relation to
various clinicopathological characteristics, tumor proliferative capacity and patients' survival.
Results: HSP-27, -60, -90 proteins were abundantly expressed in gastric adenocarcinoma cases
examined. HSP-27 expression was significantly associated with tumor size (pT, P = 0.026), the
presence of organ metastases (pM, P = 0.046) and pStage (P = 0.041), while HSP-27 staining
intensity with nodal status (pN, P = 0.042). HSP-60 expression was significantly associated with
patients' sex (P = 0.011), while HSP-60 staining intensity with patients' age (P = 0.027) and tumor
histopathological grade (P = 0.031). HSP-90 expression was not associated with any of the
clinicopathological parameters examined; however, HSP-90 staining intensity was significantly
associated with tumor size (pT, P = 0.020). High HSP-90 expression was significantly associated
with longer overall survival times in univariate analysis (log-rank test, P = 0.033), being also
identified as an independent prognostic factor in multivariate analysis (P = 0.026).
Conclusion: HSP-27, -60, and -90 were associated with certain clinicopathological parameters
which are crucial for the management of gastric adenocarcinoma patient. HSP-90 expression may
also be an independent prognostic indicator in gastric adenocarcinoma patients.
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1. Background
Heat shock proteins (HSPs) are ubiquitous, highly con-
served proteins across all species, which are strongly
induced by heat shock and diverse environmental and
physiopathological stresses [1,2]. HSPs constitute the
products of several distinct genes commonly designated
according to their mass [1-3]. Their principal function as
molecular chaperones results in the maintenance of sta-
bility and delivery of other peptides, which are crucial for
the protection of cellular integrity in normal and malig-
nant cell growth. In absence of stress, HSPs form com-
plexes with the heat shock transcription factors (HSFs),
which remain in an inactive form [4]. During stress condi-
tions, HSPs repress chaperones and link to misfolded pro-
teins, which allows the activation of HSF through
phosphorylation by protein kinases (PK), such as PKC
and serine/threonine kinases [4-6]. Hence, HSF forms a
homotrimeric structure in the cytosol and translocate to
the nucleus, binding to heat shock elements (HSEs) in
order for the transactivation of heat shock-inducible genes
to be elicited [4-6].
Aside from their response to heat shock and chemical or
physical stress stimuli, HSPs have been reported to be
overexpressed in a wide range of human tumors including
breast, endometrial, ovarian, colon, lung and prostate [7].
The expression of several HSPs has also been shown to
correlate with tumor cell proliferation and differentiation,
as well as apoptosis-related molecules in various types of
cancer [7]. Currently, several drugs have been advanced in
clinical studies rendering HSPs as emerging therapeutic
targets in fighting cancer [4,7]. To this point of view, HSP-
90 targeted drugs, such as 17AAG and SNX2112, are cur-
rently being advanced in order to selectively inhibit HSP-
90 in tumor cells, without affecting its function in normal
ones [4,8-10].
Gastric cancer constitutes one of the most common malig-
nant tumors in Asian countries [11,12]. Although its inci-
dence in West countries is lower than those in Asia, it
remains a major health problem, representing the second
cause of cancer-related deaths worldwide [11,12]. Helico-
bacter pylori infection and to a lesser extent smoking have
been identified as the main environmental risk factors for
gastric cancer [13,14]. Recent evidence suggested that
HSPs may have a close relationship with gastric neoplasia
[15-21]. However, there is little information about their
clinical relevance in the management and prognosis of
patients with this type of cancer.
The present study aimed to estimate the extent of the
immunohistochemical expression of HSP-27, -60 and -90
proteins in tumoral specimens obtained from gastric can-
cer patients. We also aimed to evaluate the association
between the extent and intensity of expression of HSP
staining and various clinicopathological parameters,
tumor proliferative capacity, and patients' survival.
2. Methods
2.1. Patients
Sixty-six gastric carcinoma specimens obtained from an
equal number of patients who underwent surgical resec-
tion due to gastric cancer were included in this study. This
study was approved by the ethical committee of Laikon
General Hospital. None of the patients received any kind
of anti-cancer treatment prior to surgery. Forty-seven of
the patients were men (71%) and 19 (29%) women. The
mean age of the patient cohort was 67.5 ± 8.6 years
(median: 67 years, range: 39–88 years). Tumors were cat-
egorized according to Lauren classification [22] as: intesti-
nal type in 30 (45%) and diffuse type in 36 (55%) out of
66 cases. Three levels of differentiation were used to clas-
sify grading as: well (n = 3, 5%), moderately (n = 30, 45%)
and poorly differentiated (n = 33, 50%). Tumors staging
was assessed using the 5th edition of the Tumor, Node,
Metastasis (TNM) system according to the Union Interna-
tionale Contra la Cancrum (UICC) and the American
Joint Committee on Cancer (AJCC) [23]; they were classi-
fied asT1 (n = 9, 14%), T2 (n = 22, 33%), T3 (n = 29, 44%)
and T4 (2 = 6, 9%). Twenty-four (36%) patients were
node negative (N0), and 42 (64%) node positive (N1, n =
38, 58% and N2, n = 4, 6%). Organ metastasis was noted
in 7 (11%) out of 66 patients examined. Sixty three
patients were followed up for a median of 24 months
(mean 28.9 ± 22.3 months, range 1–104 months).
2.2 Immunohistochemistry
Immunostainings for HSP-27, -60 and -90 were per-
formed on paraffin-embedded tissue sections using com-
mercially available goat anti-human HSP-27, HSP-60 and
HSP-90 (Santa Cruz Biochemicals, Santa Cruz, CA, USA)
primary antibodies. Briefly, 4 μm thick tissue sections
were dewaxed in xylene and were brought to water
through graded alcohols. To remove the endogenous per-
oxidase activity, sections were then treated with freshly
prepared 0.3% hydrogen peroxide in methanol in the
dark, for 30 minutes, at room temperature. Non-specific
antibody binding was then blocked using Eraser, a specific
blocking reagent for goat primary antibodies (Eraser, Bio-
care Medical, Walnut, Creek, CA, USA) for 8 min. Antigen
immunoreactivity was detected by incubation with pri-
mary antibodies at a 1:100 dilution, in phosphate buff-
ered saline (PBS) for one hour, at room temperature,
according to the manufactures' instructions. After washing
three times with PBS, sections were incubated for 30 min-
utes at room temperature with biotinylated linking rea-
gent donkey, anti-goat immunoglobulins diluted 1:150 in
PBS (Santa Cruz Biochemicals, Santa Cruz, CA, USA), and
rinsed three times with PBS. The sections were then incu-
bated with peroxidase-conjugated streptavidin labelBMC Gastroenterology 2009, 9:14 http://www.biomedcentral.com/1471-230X/9/14
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(Dakopatts, Glostrup, Denmark), for 20 minutes. The
resultant immune peroxidase activity was developed in
0.5% 3,3'-diaminobenzidine hydrochloride (DAB; Sigma,
Saint Louis, MO, USA) in PBS containing 0.03% hydrogen
peroxide for 3 minutes. Sections were counterstained with
Harris' hematoxylin and mounted in Entellan (Merck,
Darmstadt, Germany). Appropriate negative controls
were performed by omitting the primary antibody and/or
substituting it with an irrelevant anti-serum. As positive
controls paraffin-embedded liver sections with known
immunoreactivity for HSPs were used.
The tumors' proliferative capacity was assessed immuno-
histochemically, using a mouse anti-human Ki-67 anti-
gen; IgG1k  antibody (clone MIB-1, Dakopatts) as
previously described [24]. An additional step of antigen
retrieval (citrate buffer at pH 6.1 and microwave heating)
was performed before incubation with the primary Ki-67
antibody.
The percentages of positively stained cells were obtained
by counting at least 1000 cells in each case by two inde-
pendent observers (S.T. and S.V.) blinded to the clinical
data with complete observer agreement. Specimens were
considered "positive" for HSPs when more than 5% of the
tumor cells were stained, while they were characterized to
present "high expression" for HSPs when the percentage
of positively stained cells exceeded the mean percentage
value [24]. The intensity of HSP expression was also esti-
mated and graded on a three step scale as: mild (+), mod-
erate (++) and intense (+++) [24].
2.3 Statistical Analysis
Chi-square and Fisher's exact tests were used to assess the
association between HSP-27, -60 and -90 overexpression
and intensity of immunostaining and clinicopathological
variables. Spearman rank correlation was used to assess
the correlation amongst HSP-27, -60 and -90 protein
expressions. Survival curves were constructed using the
Kaplan-Meier method and compared using the log-rank
test. Cox proportional hazard regression analysis was used
to evaluate the effect of HSP-27, -60 and -90 expression
and intensity of staining as prognostic factors on patients'
survival. A 2-tailed P < 0.05 was considered (statistically)
significant. Statistical analyses were performed using the
software package SPSS for Windows (version 11.0; SPSS
Inc., Chicago, IL, USA).
3. Results
HSP-27, -60, -90 proteins were abundantly expressed in
gastric adenocarcinoma cases examined, presenting
mainly a cytoplasmic and occasionally membraneous pat-
tern of staining. Representative immunostainings for
HSP-27, -60 and -90 are illustrated in Figure 1A–C.
The mean HSP-27 expression value was 52%, while the
incidence of tumors with high HSP-27 expression was
50% (33 out of 66 cases) (Table 1). The intensity of HSP-
27 immunostaining was classified as mild in 20 (30%),
moderate in 40 (61%) and intense in 6 (9%) cases. In
cross-tables, HSP-27 expression was significantly associ-
ated with tumor size (pT, P = 0.026), the presence of organ
metastases (pM, P = 0.046) and pStage (P = 0.041), while
a trend was showed with lymph node positivity (pN, P =
0.078). HSP-27 intensity of staining was significantly
associated with lymph node positivity (pN, P = 0.042),
while with patients' age was borderline significant (P =
0.070) (Table 1).
The mean HSP-60 expression value was 52%, while the
incidence of tumors with high HSP-60 expression was
55% (36 out of 66 cases) (Table 2). The intensity of HSP-
60 immunostaining was classified as mild in 21 (32%),
moderate in 32 (48%) and intense in 13 (20%) cases. In
cross-tables, HSP-60 expression was significantly associ-
ated with patient sex (P = 0.011), while a trend was found
with tumor histological grade (P = 0.053) and tumor pro-
liferative capacity (Ki-67 statement, P = 0.077). HSP-60
intensity of staining was significantly associated with
patients' age (P = 0.027) and tumor histopathological
grade (P = 0.031) (Table 2).
The mean HSP-90 expression value was 48%, while the
incidence of tumors with high HSP-90 expression was
50% (33 out of 66 cases) (Table 3). The intensity of HSP-
90 immunostaining was classified as mild in 30 (45%),
moderate in 31 (47%) and intense in 5 (8%) cases. In
cross-tables, HSP-90 expression was not significantly asso-
ciated with any of the clinicopathological parameters
examined. HSP-90 intensity of staining was significantly
associated with tumor size (pT, P = 0.020). A borderline
association (P = 0.070) between HSP-90 intensity of stain-
ing and histopathological type was also noted (Table 3).
We calculated the Spearman's rank correlation coefficient
to evaluate the linear relationships amongst the extent of
expression of HSP-27, -60 and -90 proteins (Table 4). Sig-
nificant positive correlations were obtained between the
HSP-27 percentage expression and that of HSP-60 and -90
(rs = 0.47, P < 0.001 and rs = 0.32, P = 0.008, respectively).
A significant positive correlation was also found between
the extent of HSP-60 and HSP-90 expressions (rs = 0.25, P
= 0.044) (Table 4).
The Kaplan-Meier product-limit method for overall sur-
vival analysis according to HSP-27 or -60 expression (low
vs high HSP-27 or -60 proteins expression) in gastric ade-
nocarcinoma specimens did not reveal significant associ-
ations (log-rank test, P = 0.478 or P = 0.953, respectively).
Univariate analysis showed significant difference in theBMC Gastroenterology 2009, 9:14 http://www.biomedcentral.com/1471-230X/9/14
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survival times of gastric cancer patients with respect to
HSP-90 expression (low vs high) (log-rank test, P = 0.033)
(Figure 2A). Multivariate survival Cox regression analysis
also showed statistical significance for HSP-90 expression
(P = 0.026). No significant associations between HSP-27,
-60 and -90 intensity of immunostaining and patients'
survival were noted (P = 0.577, P = 0.094 and P = 0.299,
respectively). To further evaluate the association of HSP-
27, -60 and -90 intensity of staining with patients' sur-
vival, we grouped carcinomas which had moderate or
intense intensity of staining together and opposed them
to cases with mild intensity. In this context, no significant
associations were noted for HSP-27, -60 and -90 immu-
nostainings (P = 0.965, P = 0.551 and P = 0.072, respec-
tively).
To assess if HSPs bear a pronounced prognostic effect in
patient subgroups, we conducted an extensive Kaplan-
Meier analysis of HSP-27, -60 and -90 protein expressions
(low vs high) and intensity of staining (mild vs moderate
and intense). We stratified by pT stage (small vs  large
tumor size, pT1/T2 vs pT3/T4), tumor grading (poorly vs
moderately and well differentiated), nodal status
(absence vs presence of lymph node metastases, pN0 vs
pN1/N2), presence of organ metastases (pM0 vs  pM1)
and histopathological type (intestinal vs diffuse). Stratify-
ing for histological type, HSP-90 expression and intensity
of immunostaining were associated with longer overall
survival times in intestinal type gastric cancer cases, with-
out though reaching statistical significance (log-rank test,
P = 0.069, P = 0.064, respectively). Such an association
was not seen in diffuse type (log-rank test, P = 0.373)
(data not shown). In the subgroup of lymph node nega-
tive gastric cancer cases (pN0), high HSP-90 expression
was significantly associated with longer survival times (P
= 0.042) (Figure 2B); however, this association did not
remain in the multivariate analysis (P = 0.111). In the
subgroup of well and moderately differentiated (G1/G2)
gastric cancer cases, high HSP-90 expression was signifi-
cantly associated with longer overall survival times (P =
0.036) (Figure 2C), being also identified as an independ-
ent prognostic factor in multivariate analysis (P = 0.018),
which was not seen in poorly differentiated (G0) gastric
cancer cases (P = 0.754). Stratifying for organ metastasis,
in negative cancer cases (pM0), high HSP-90 expression
was significantly associated with longer overall survival
time (P = 0.027) (Figure 2D), being also identified as an
independent prognostic factor in multivariate analysis (P
= 0.032). No significant associations of HSP-27, -60 and -
90 expression or intensity of immunostaining with
patients' survival were noted in all the other examined
subgroups of patients (data not shown).
4. Discussion
HSPs have been reported to be overexpressed in a wide
range of human tumors, while HSPs expression has been
associated with tumor cell growth and differentiation, as
well as with resistance to apoptosis and poor prognosis
[7]. There is also relatively recent evidence to support that
HSPs are overexpressed in human gastric cancer and may
contribute to the development and prognosis of this type
of cancer [7].
The present study further supports the clinical significance
of HSP-27, -60 and -90 protein expression in the progres-
sion of gastric cancer. All examined cases of gastric adeno-
carcinoma were tested positive for HSP-27, -60 and -90.
This incidence of HSP-27, -60 and -90, positivity is among
the highest reported for this specific type of tumor malig-
nancy. Both Takano et al. and Kapranos et al. reported a
lower incidence of HSP-27 positivity: 52.4% (22/42) and
62.7% (54/86), respectively [20,21]. In addition, concern-
ing HSP-70 and HSP-40, two other members of HSPs fam-
ily, positive staining was noted at a percentage of 67.9%
(55/81) and 22.2% (18/81) of gastric cancer cases [15].
However, Zuo et al. reported results similar to ours with
HSP-90α positivity of 95% (84/88) [18].
The present study further showed that HSP-27, -60 and -
90 were highly expressed in gastric cancer tissues with
mean percentage expression values of 52, 52 and 48%,
respectively. Overexpression concerning a group of HSPs,
including HSP-60, HSP-70 and Chaperonin containing
TCP1 (CCT), a member of HSP-60 family, in a rather low
sample of 10 primary gastric adenocarcinoma cases was
reported by proteomic analysis. The authors suggested
that this overexpression may be attributed to the stress
response and self-protective effort of the cells during
Representative cases of HSPs protein expression in tumor  cells of gastric adenocarcinoma: A. HSP-27 B. HSP-60. C.  HSP-90 (original magnification ×200) Figure 1
Representative cases of HSPs protein expression in 
tumor cells of gastric adenocarcinoma: A. HSP-27 B. 
HSP-60. C. HSP-90 (original magnification ×200).BMC Gastroenterology 2009, 9:14 http://www.biomedcentral.com/1471-230X/9/14
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malignant transformation [17]. However, the exact
molecular mechanisms through which HSPs become
overexpressed in cancer remain to be clarified. Overall,
the available data so far suggest that HSPs may well be
related to the genetic changes implicated in tumor pro-
gression. Oncoproteins may appear during carcinogene-
sis, such as mutated p53, and these mutated and
conformationally altered proteins may elicit an HSP
response [1].
Significant positive correlations (Spearmen rank correla-
tion) were found between the extent of HSP-27 expression
and that of HSP-60 and -90 proteins (Table 4). A lower
correlation (Spearmen rank correlation) between the
expression of HSP-60 and that of HSP-90 was also
obtained (Table 4). However, in another study involving
oesophageal squamous cell carcinoma, no correlation
between HSP-60 and HSP-90 was reported [25].
In the present study, HSP-27 expression and intensity of
immunostaining were found to be associated with impor-
tant clinicopathological characteristics for patients' man-
agement. This result is in line with previous evidence that
HSP-27 expression was reported to be associated with
lymph node metastases in 86 human gastric carcinoma
samples [21]. Consistently, in our study, significant and
borderline associations between HSP-27 intensity and
expression of immunostaining and nodal status were
found, respectively. In addition, HSP-27 expression was
significantly associated with the presence of organ metas-
tasis, tumor size and pStage. However, HSP-27 expression
and staining intensity were not associated with patients'
survival. In this context, Kapranos et al. demonstrated that
Table 1: HSP-27 expression and intensity of staining and clinicopathological characteristics of the 66 patients with gastric 
adenocarcinoma
Clinicopathological Characteristics HSP-27 expression HSP-27 intensity
n = 66 < 52%(%) ≥ 52% (%) p-value +(%) ++(%) +++(%) p-value
All cases 33(50) 33(50) 20(30) 40(61) 6(9)
Age 0.796 0.070
< 67 12(18) 11(17) 10(15) 13(20) 0(0)
≥ 67 21(32) 22(33) 10(15) 27(41) 6(9)
Sex 0.415 0.892
Male 22(33) 25(38) 15(23) 28(43) 4(6)
Female 11(17) 8(12) 5(7) 12(18) 2(3)
Histological type 0.460 0.628
Intestinal 15(23) 15(23) 8(12) 20(30) 2(3)
Diffuse 18(27) 18(27) 12(18) 20(31) 4(6)
Histological grade 0.566 0.266
Well differentiated 1(2) 2(3) 1(2) 2(3) 0(0)
Moderately differentiated 17(25) 13(20) 7(10) 22(34) 1(2)
Poorly differentiated 15(23) 18(27) 12(18) 16(24) 5(7)
pT classification 0.026 0.661
T1 7(11) 2(3) 5(7) 4(6) 0(0)
T2 10(15) 12(18) 6(9) 14(21) 2(3)
T3 16(24) 13(20) 8(12) 18(28) 3(4)
T4 0(0) 6(9) 1(2) 4(6) 1(2)
pN classification 0.078 0.042
N0 13(20) 11(17) 6(9) 16(24) 2(3)
N1 16(24) 22(33) 10(15) 24(37) 4(6)
N2 4(6) 0(0) 4(6) 0(0) 0(0)
pM classification 0.046 0.593
M0 32(48) 27(41) 17(26) 37(57) 5(7)
M1 1(2) 6(9) 3(4) 3(4) 1(2)
pStage 0.041 0.162
I 14(21) 6(9) 8(12) 12(18) 0(0)
II 7(11) 10(15) 2(3) 11(17) 4(6)
III 11(17) 19(29) 7(11) 13(20) 1(2)
IV 1(2) 7(10) 3(4) 4(6) 1(2)
Ki-67 protein statement 0.269 0.865
< 75 26(39) 22(33) 14(21) 30(45) 4(6)
≥ 75 7(11) 11(17) 6(9) 10(16) 2(3)BMC Gastroenterology 2009, 9:14 http://www.biomedcentral.com/1471-230X/9/14
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HSP-27 expression in 86 gastric cancer specimens was
associated with shorter overall survival in univariate anal-
ysis; however, this relationship was not remained in mul-
tivariate analysis [21]. Moreover, according to Takano et
al., univariate analysis of 42 tissue samples from patients
with resectable stage IV gastric cancer showed that pN fac-
tors, blood vessel invasion, HSP-27 overexpression and
the index of p53 and HSP-27 overexpression exhibited a
prognostic influence [20]. However, only the Lauren clas-
sification was sustained as an independent variable in the
multivariate analysis [20]. Furthermore, we found that
patients with diffuse type of gastric cancer were character-
ized by shorter survival times when compared with those
with intestinal type; however, this difference did not reach
statistical significance (log-rank test, p = 0.083, data not
shown). Both Maehara et al. and Isomoto et al. also did
not find any significant association between HSPs expres-
sion and patient survival [15,16]. In fact, histopathologi-
cal differentiation was significantly correlated with the
expression of HSP-70, whereas no impact of HSP-70 and
HSP-40 expression on any factors predicting prognosis
and survival was noted [15,16]. Another study by Wang et
al. further revealed a significant correlation between the
expression of HSP-72 and gp96 and the progression of
gastric carcinomas [26].
HSP-60 expression was significantly associated with
patient sex, with only borderline associations with tumor
histopathological grade and proliferative capacity
reflected by Ki-67 labelling index. In fact, higher HSP-60
expression was found in female compared to male
patients, while poorly differentiated tumors more fre-
quently expressed higher levels of HSP-60 compared to
well and moderate differentiated ones. In addition, HSP-
60 staining intensity was significantly associated with
patients' age and tumor histopathological grade. Accord-
Table 2: HSP-60 expression and intensity of staining and clinicopathological characteristics of the 66 patients with gastric 
adenocarcinoma
Clinicopathological Characteristics HSP-60 expression HSP-60 intensity
n = 66 < 52%(%) ≥ 52% (%) p-value +(%) ++(%) +++(%) p-value
All cases 30(45) 36(55) 21(32) 32(48) 13(20)
Age 0.187 0.027
< 67 13(20) 10(15) 10(15) 6(9) 7(11)
≥ 67 17(25) 26(40) 11(17) 26(39) 6(9)
Sex 0.011 0.436
Male 26(40) 21(32) 17(26) 22(33) 8(12)
Female 4(5) 15(23) 4(6) 10(15) 5(8)
Histological type 0.191 0.851
Intestinal 11(16) 19(29) 10(15) 15(22) 5(8)
Diffuse 19(29) 17(26) 11(17) 17(26) 8(12)
Histological grade 0.053 0.031
Well differentiated 3(4) 0(0) 3(4) 0(0) 0(0)
Moderately differentiated 10(15) 20(30) 7(11) 19(28) 4(6)
Poorly differentiated 17(26) 16(25) 11(17) 13(20) 9(14)
pT classification 0.239 0.298
T1 5(7) 4(5) 4(6) 5(8) 0(0)
T2 8(12) 14(22) 8(12) 10(15) 4(6)
T3 16(24) 13(21) 9(14) 14(21) 6(10)
T4 1(2) 5(7) 0(0) 3(4) 3(4)
pN classification 0.250 0.213
N0 14(21) 10(15) 10(15) 11(17) 3(4)
N1 14(21) 24(37) 9(14) 19(28) 10(16)
N2 2(3) 2(3) 2(3) 2(3) 0(0)
pM classification 0.884 0.230
M0 27(41) 32(49) 20(30) 29(45) 10(17)
M1 3(4) 4(6) 1(2) 3(3) 3(3)
pStage 0.114 0.649
I 10(15) 10(15) 8(12) 9(14) 3(4)
II 4(5) 13(21) 5(7) 10(15) 2(3)
III 13(21) 8(12) 7(11) 9(14) 5(9)
IV 3(4) 5(7) 1(2) 4(5) 3(4)
Ki-67 protein statement 0.077 0.913
< 75 25(38) 23(34) 15(23) 24(36) 9(14)
≥ 75 5(7) 13(21) 6(9) 8(12) 4(6)BMC Gastroenterology 2009, 9:14 http://www.biomedcentral.com/1471-230X/9/14
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ingly, Cappello et al. showed that HSP-60 expression was
associated with tumor grade in advanced large bowel car-
cinomas with lymph node metastases [27]. HSP-60 was
also reported to be overexpressed early in prostate and
colorectal carcinogenesis [28,29]. Moreover, it was sup-
ported that HSP-60 may be a novel biomarker during
bronchial carcinogenesis [30]. On the other hand,
although HSP-60 expression was not associated with any
clinicopathological parameters in oesophageal squamous
cell carcinoma patients, it was significantly associated
with the apoptotic index and patient prognosis [25]. In
contrast, we did not find any significant association of
HSP-60 expression or staining intensity with the progno-
sis of patients with gastric cancer. To our knowledge, prior
Table 3: HSP-90 expression and intensity of staining and clinicopathological characteristics of the 66 patients with gastric 
adenocarcinoma
Clinicopathological Characteristics HSP-90 expression HSP-90 intensity
n = 66 < 48%(%) ≥ 48% (%) p-value +(%) ++(%) +++(%) p-value
All cases 33(50) 33(50) 30(45) 31(47) 5(8)
Age 0.196 0.629
< 67 14(21) 9(14) 12(18) 10(15) 1(2)
≥ 67 19(29) 24(36) 18(27) 21(32) 4(6)
Gender 0.786 0.276
Male 23(35) 24(36) 22(33) 23(35) 2(3)
Female 10(15) 9(14) 8(12) 8(12) 3(5)
Histological type 0.621 0.070
Intestinal 14(21) 16(24) 13(20) 17(25) 0(0)
Diffuse 19(29) 17(26) 17(25) 14(22) 5(8)
Histological grade 0.834 0.661
Well differentiated 2(3) 1(2) 2(3) 1(2) 0(0)
Moderately differentiated 15(22) 15(24) 14(21) 15(22) 1(2)
Poorly differentiated 17(25) 15(24) 14(21) 15(23) 4(6)
pT classification 0.240 0.020
T1 7(11) 2(3) 8(12) 1(2) 0(0)
T2 9(14) 13(20) 7(10) 14(22) 1(2)
T3 15(22) 14(21) 13(20) 14(21) 1(2)
T4 2(3) 4(6) 2(3) 2(3) 2(4)
pN classification 0.873 0.985
N0 13(20) 11(17) 11(17) 11(17) 2(3)
N1 18(27) 20(30) 17(25) 18(27) 3(5)
N2 2(3) 2(3) 2(3) 2(3) 0(0)
pM classification 0.689 0.530
M0 29(44) 30(46) 26(40) 29(44) 4(6)
M1 4(6) 3(4) 4(5) 2(3) 1(2)
pStage 0.250 0.114
I 12(18) 8(12) 10(15) 10(15) 0(0)
II 5(8) 12(18) 7(10) 7(11) 3(5)
III 12(18) 9(14) 9(14) 12(18) 0(0)
IV 4(6) 4(6) 4(6) 2(3) 2(3)
Ki-67 protein statement 1.000 0.260
< 75 24(36) 24(36) 23(35) 20(30) 5(8)
≥ 75 9(14) 9(14) 7(10) 11(17) 0(0)
Table 4: Spearman rank correlations amongst the HSP-27, -60 and -90 proteins extent of expression in the 66 gastric tumoral 
specimens
n = 66 HSP-27 HSP-60 HSP-90
HSP-27 -r s = 0.47, P < 0.001 rs = 0.32, P = 0.008
HSP-60 rs = 0.47, P < 0.001 - rs = 0.25, P = 0.044
HSP-90 rs = 0.32, P = 0.008 rs = 0.25, P = 0.044 -BMC Gastroenterology 2009, 9:14 http://www.biomedcentral.com/1471-230X/9/14
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to the current study, there was no available data concern-
ing the clinical significance of HSP-60 expression in rela-
tion to clinicopathological parameters in gastric cancer.
According to our results, HSP-90 protein expression was
not associated with any of the examined clinicopatholog-
ical characteristics. However, HSP-90 intensity of immu-
nostaining was significantly associated with tumor size,
and borderline with histological type. Overall, the diag-
nostic value of HSP-90 expression has been examined in
several types of cancers; however, most of the studies so
far did not find significant associations with clinicopatho-
logical characteristics [7]. With respect to gastric cancer, a
significant association was reported by Zuo et al. between
HSP-90α expression and lymph node metastases [18]. In
addition, enhanced HSP-90β expression was also demon-
strated in human gastric cancer tissues and especially in
poorly differentiated types [19]. In vitro studies also
showed that HSP-90β expression was greater in SGC7901/
VCR of MDR-type gastric cell line than in its parental cell
line SGC7901 [19].
To our knowledge, there is no available evidence so far
concerning the prognostic value of HSP-90 expression in
gastric cancer. In this respect, the current study is the first
report examining the clinical significance of HSP-90
expression in the prognosis of patients with gastric aden-
ocarcinoma. On univariate survival analysis, higher HSP-
90 protein expression was associated with longer overall
survival times. Moreover, the multivariate survival analy-
sis showed that HSP-90 protein expression was a signifi-
cant independent prognostic factor for gastric
adenocarcinoma patients. In the clinically distinctive sub-
groups of node-negative, well and moderately differenti-
ated and organ metastasis-negative tumors, high HSP-90
protein expression was also associated with favorable
prognosis. Moreover, HSP-90 expression and intensity of
immunostaining showed a trend to be associated with
overall survival times in intestinal type, but not in diffuse
type gastric cancer cases. The contradictory prognostic
value of HSP-90 overexpression between diffuse and
intestinal type of gastric cancer patients could be attrib-
uted to the different signals produced from the tumor
microenvironment and the individual cellular characteris-
tics of each tumor histological type. Such distinct charac-
teristics could trigger tumoral cells to upregulate or
downregulate HSP-90 signalling in respect to tumor histo-
logical type. The prognostic value of HSP-90 expression
has also been examined in several types of cancer. In
agreement with our results, HSP-90 expression was signif-
icantly associated with favorable prognosis in endome-
trial cancer [31,32]. In contrast, HSP-90 expression in
cancer tissues and the presence of autoantibodies to HSP-
90 have been associated with poor prognosis in breast
cancer [33], while it was found to be of no prognostic
value in ovarian and oral carcinomas [25,34,35]. The
present data that HSP-90 expression is associated with
improved survival deserves special attention, as it could
be implied that loss of chaperoning, such as HSP-90, may
lead to a more aggressive phenotype, thus leading to poor
prognosis or resistance to therapy. In this context, block-
ing HSP-90 was shown to disrupt multiple proangiogenic
signaling pathways in gastric cancer cells and inhibit
xenografted tumor growth in vivo [36]. Hence, gastric can-
cer harbors attractive molecular targets for therapy with
HSP-90 inhibitors, which could lead to improved efficacy
of antineoplastic therapy regimens [36].
5. Conclusion
The current study suggested that the expression of HSP-
27, -60 and -90 proteins was associated with important
clinicopathological parameters in respect to the diagnosis
of patients with gastric cancer. HSP-27 and -60 failed to
predict patients' prognosis, whereas HSP-90 was shown to
be an independent prognostic indicator in patients with
gastric cancer. Further research is required in order to clar-
ify the mechanisms through which HSPs' regulation
affects the molecular events involved in tumor growth,
invasiveness and metastases. Such studies could be essen-
tial for the development of new therapeutic strategies,
such as HSP-90 inhibitors, and promising prognostic
indicators in gastric cancer. It was also suggested that
depending on their mode of induction, intracellular/
extracellular location, cellular origin (eukaryote/prokary-
ote), peptide loading status, intracellular ADP/ATP con-
Kaplan-Meier survival analysis stratified according to HSP-90  expression in patients with gastric cancer Figure 2
Kaplan-Meier survival analysis stratified according to 
HSP-90 expression in patients with gastric cancer. A. 
All cases. B. Subgroup of pN0 cases. C. Subgroup of G1/G2 
cases. D. Subgroup of pM0 cases. (Red dashed line, high HSP-
90 expression; Blue continuous line, low HSP-90 expression).
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tent, concentration, and route of application, HSPs may
either exert immune activation as danger signals in cancer
immunity and mediate protection against infectious dis-
eases or exhibit regulatory activities in controlling and
preventing autoimmunity [37]. In this context, further
studies should be conducted on measuring serum HSPs
levels in order to delineate whether there is a link between
intracellular and extracellular HSPs levels in gastric neo-
plasia.
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